Dragon Pharmaceutical Addresses that Its Stock Is Traded on the Berlin-Bremen...
Dragon Pharmaceutical Inc. (TSX: DDD, OTC BB: DRUG) announced today that it has learned that Dragon’s stock has been traded on the Berlin-Bremen Stock Exchange without any prior knowledge from the...
View ArticleDragon Announces Receiving Common Shares in Escrow from Dr. Liu pursuant to...
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) today announced that 2.23 million common shares of the Company have been placed in escrow by Dr. Liu, a director of the Company, to secure...
View ArticleDragon Reports Second Quarter Results of 2004
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) is pleased to announce the results for the second quarter ended June 30, 2004. For the three-month ended June 30, 2004 During the second...
View ArticleDragon Reports Record Third Quarter Revenue
Dragon Pharmaceuticals Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and nine-month periods ending September 30, 2002. For greater detail, please refer to the Company’s...
View ArticleDragon Announces Update on Business Strategy
Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has undertaken to reevaluate its corporate strategy following the appointment of Dr. Alexander Wick as President in October...
View ArticleDragon Launches EPO Into the Brazilian Market
Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a...
View ArticleDragon Pharmaceuticals Appoints James Harris as VP of Sales and Marketing
Dragon Pharmaceuticals Inc. (TSX: DDD; OTC BB: DRUG) is pleased to announce that it has appointed James Harris as VP of Sales and Marketing, replacing Robert Walsh. He will be responsible for...
View ArticleDragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights * Generated revenues of $7.36 million,...
View ArticleDragon Receives Approval for the Use of EPO in Surgical Patients and New...
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced that it has received market approval from the Chinese State Drug Administration (SDA) for the use of rHu Erythropoietin (EPO) in...
View ArticleDragon Reports First Quarter Results of 2003
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) announced results for the three-month period ending March 31, 2003. During the quarter, the Company posted revenues of $664,322 from the sales of rHu...
View Article